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Pyrintegrin Induces Soft Tissue 
Formation by Transplanted or 
Endogenous Cells
Bhranti S. Shah1,2, Mo Chen1, Takahiro Suzuki1, Mildred Embree1, Kimi Kong1, Chang H. Lee1, 
Ling He1,3, Lusai Xiang1,3, Jeffrey A. Ahn1, Sheng Ding4 & Jeremy J. Mao1,2,3
Focal adipose deficiency, such as lipoatrophy, lumpectomy or facial trauma, is a formidable challenge 
in reconstructive medicine, and yet scarcely investigated in experimental studies. Here, we report that 
Pyrintegrin (Ptn), a 2,4-disubstituted pyrimidine known to promote embryonic stem cells survival, is 
robustly adipogenic and induces postnatal adipose tissue formation in vivo of transplanted adipose 
stem/progenitor cells (ASCs) and recruited endogenous cells. In vitro, Ptn stimulated human adipose 
tissue derived ASCs to differentiate into lipid-laden adipocytes by upregulating peroxisome proliferator-
activated receptor (PPARγ) and CCAAT/enhancer-binding protein-α (C/EBPα), with differentiated cells 
increasingly secreting adiponectin, leptin, glycerol and total triglycerides. Ptn-primed human ASCs 
seeded in 3D-bioprinted biomaterial scaffolds yielded newly formed adipose tissue that expressed 
human PPARγ, when transplanted into the dorsum of athymic mice. Remarkably, Ptn-adsorbed 3D 
scaffolds implanted in the inguinal fat pad had enhanced adipose tissue formation, suggesting Ptn’s 
ability to induce in situ adipogenesis of endogenous cells. Ptn promoted adipogenesis by upregulating 
PPARγ and C/EBPα not only in adipogenesis induction medium, but also in chemically defined medium 
specifically for osteogenesis, and concurrently attenuated Runx2 and Osx via BMP-mediated SMAD1/5 
phosphorylation. These findings suggest Ptn’s novel role as an adipogenesis inducer with a therapeutic 
potential in soft tissue reconstruction and augmentation.
Focal soft tissue defects frequently represent substantial loss of adipose tissue such as that resulting from breast 
cancer resection, facial trauma or congenital anomalies1–3. Despite a significant challenge for surgical recon-
struction, focal adipose deficiency is scarcely investigated in experimental approaches of tissue regeneration4,5. 
Adipose tissue regeneration offers several advantages over the current treatment modalities such as autolo-
gous grafting and commercially available fillers such as fibrin, hyaluronic acid, collagen for treating focal tissue 
defects4,6. Several stem cell sources have been utilized for soft tissue engineering: bone marrow7–11, abdominal 
fat8,12–17, ligament etc.15. Progenitor cells from adipose tissue consistently differentiate into lipid-laden adipocytes 
in vitro2,8,10,11,16.
Adipogenic differentiation of stem/progenitor cells is achieved using adipogenic induction medium, typi-
cally with a combination of insulin, dexamethasone, indomethacin and methylisobutylxanthine (IBMX), which 
elevates intracellular cAMP levels, in the presence of fetal bovine serum2,10,11,16–18. Adipogenic differentiation of 
stem/progenitor cells is primarily gated by two families of transcription factors, peroxisome proliferator-activated 
receptor-γ (PPARγ ) and CCAT/enhancer binding protein (CEBPs)19–21. PPARγ , a member of the nuclear hor-
mone receptor family, is expressed upon stem/progenitor cell commitment to differentiate towards adipocytes22,23. 
The C/EBPs belong to the basic-leucine zipper class of transcription factors24,25. C/EBPα , β , δ isoforms form a 
homo- and/or heterodimer configuration via a highly conserved bZIP domain26,27. C/EBPα alone or with PPARγ 
promotes adipose cell differentiation of fibroblasts or myoblasts28,29. Therefore, orchestrated regulation between 
PPARγ and C/EBPs may be crucial in initiating and maintaining the differentiated state of adipocytes23,26.
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Small molecules that regulate adipocyte differentiation have been explored, including phenamil30, harmine31, 
SR6452, a synthetic REV-ERB ligand32 and known PPARγ agonists such as Troglitazone33,34, Rosiglitazone35–37, 
Pioglitazone38–40. The majority of these small molecules act via PPARγ pathway and facilitate adipogenesis 
in vitro. Activation of PPARγ receptor has been shown to promote adipogenesis and inhibit osteogenesis in bone 
marrow stem/stromal cells41. In this report, we discovered that Pyrintegrin (Ptn), a small molecule identified 
through high-throughput screening for its ability to promote the survival of human embryonic stem cells42, not 
only attenuated Runx2 and Osx via BMP-mediated SMAD1/5 phosphorylation, but also concurrently upregu-
lates PPARγ and C/EBPα . In vivo, Ptn-treated human ASCs in 3D-bioprinted scaffolds, when transplanted in the 
dorsum of athymic mice, yielded ectopically formed adipose tissue that expressed human PPARγ . Remarkably, 
Ptn-adsorbed collagen gel implanted in the inguinal fat pad promoted adipogenesis formed by host endogenous 
cells, suggesting its ability to induce in situ adipogenesis without the need for cell transplantation.
Results
Pyrintegrin promotes adipogenic differentiation of human adipose stem/progenitor cells in vitro. 
Passage 4–5 ASCs were plated at a density of 5 × 103 cells per cm2 and culture-expanded in 24-well plates till con-
fluence, followed by adipogenic differentiation per our prior methods20,21,28. To optimize Ptn doses, human ASCs 
were cultured in DMEM, adipogenesis induction medium (AIM), and Ptn-supplemented AIM at 2-, 5- or 10-μ M. 
PPARγ and C/EBPα expression peaked at 2-μ M Ptn, significantly more than DMEM, AIM alone and 5 or 10 μ M 
Ptn-supplemented AIM (Fig. 1A). Hence, 2-μ M Ptn dose was adopted in subsequent experiments. Lipid droplets 
were stained with fluorescent lipid dye per manufacturer’s protocol following 4-wk exposure to adipogenesis 
induction medium (AIM). Contrary to a lack of adipogenesis in DMEM, lipid accumulation occurred in AIM 
(Fig. 1B). Remarkably, Ptn at 2- μ M concentration robustly augmented lipid accumulation (Fig. 1B). However, 
Figure 1. Pyrintegrin enhances adipogenesis of human adipose stem/progenitor cells in vitro. (A) Ptn 
dose optimization by measuring PPARγ and C/EBPα expression in DMEM, AIM, AIM containing varying 
doses of Ptn 2-, 5- and 10-μM in hASC cultures after 4 days. Human GAPDH was used as the housekeeping 
gene and values representing mRNA of the DMEM group were defined as 1. AIM: adipogenesis induction 
medium; Ptn: Pyrintegrin. (B) Lipid accumulation in DMEM, AIM, AIM+Ptn 2-μM and Ptn 2-μM alone hASC 
cultures over 4 wks. Scale bar: 100 μm. (C) Relative mRNA expression of PPARγ and C/EBPα in DMEM, AIM, 
AIM+Ptn 2-μM and Ptn 2-μM alone hASC cultures at day 7. (D,E) Time-course real time RT-PCR analysis 
of  PPARγ and C/EBPα expression of DMEM, AIM and AIM+Ptn 2-μM treated hASC cultures over 28 days. 
(F–I) Supernatant analysis of adiponectin, glycerol, leptin and triglycerides measured from DMEM, AIM and 
AIM+Ptn 2-μM treated hASC cultures at 2 and 4 wks. Data are expressed as mean ± S.D. *P < 0.05.
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Ptn alone failed to induce adipogenesis (Fig. 1B), suggesting that Ptn only augments adipogenic differentiation 
in the presence of adipogenic supplements in AIM. Quantitatively, Ptn upregulated PPARγ and C/EBPα in AIM, 
significantly more than AIM alone and DMEM (Fig. 1C). Again, Ptn alone failed to upregulate PPARγ or C/EBPα 
(Fig. 1C). Human ASCs isolated from different donors were tested similarly, and were shown to exhibit similar 
lipid accumulation differences (data not shown).
Upon exposure to 2 μ M Ptn-supplemented AIM, PPARγ expression began to elevate by Day 4 and peaked 
between 7 and 14 days, followed by a decline at 21 days (Fig. 1D); C/EBPα expression began to increase by Day 4, 
and continued to escalate up to the tested 21 days (Fig. 1E), suggesting Ptn’s concerted and sequential effects on 
PPARγ and C/EBPα expression during adipogenic differentiation in ASCs. Quantitatively, ASCs secreted signifi-
cantly more levels of adiponectin, leptin, total triglycerides and glycerol (Fig. 1F–I, respectively) upon 2- or 4-wk 
exposure to 2-μ M Ptn-supplemented AIM than cells cultured in DMEM or AIM.
Pyrintegrin primed human adipose stem/progenitor cells yielded adipose tissue formation in vivo. 
A microporous scaffold was fabricated by 3D layer-by-layer apposition using 100 wt% poly-ε -caprolactone (PCL) 
with ~65 kDa molecular weight per our prior approach43,44. Cylindrical PCL scaffolds were fabricated with an 
overall dimension of 5 × 3 mm2 (diameter × height) (Fig. 2A) and with interconnecting microchannels as con-
duits to promote tissue regeneration. Interlaid strand diameters of 250–300 μ m and interconnecting microchan-
nel diameters of 400–500 μ m were selected to facilitate host cell infiltration and angiogenesis per our previous 
data43,44 (Fig. 2A). Human ASCs were culture-expanded in DMEM, AIM, or 2-μ M Pyrintegrin supplemented 
AIM for 2 wks. A total of 10 × 106 cells/mL were homogenously seeded in 3 mg/mL type I collagen solution, 
and infused into the scaffold’s microchannels (Fig. 2B), followed by incubation at 37 °C for 1 h to allow gelation. 
Subcutaneous pockets were surgically created in 8–9-wk-old athymic mice (Fig. 2B). Cell-infused or cell-free 
PCL scaffolds were implanted subcutaneously in the dorsum. Following 4-wk implantation, tissue ingrowth was 
apparent in all groups (N = 6/group) as exemplified in Fig. 2B. Cell infiltration occurred in all groups: scaffold 
alone, ASC-infused scaffolds, AIM-primed ASC scaffolds and Ptn- and AIM-treated ASC scaffolds (Fig. 2C). A 
moderate amount of adipose tissue was found in Ptn- and AIM-treated ASCs as revealed by Oil-red O staining 
(Fig. 2C). Human PPARγ expression was most pronounced in Ptn- and AIM-treated ASC scaffolds, significantly 
more than AIM-primed ASC scaffolds, ASC-infused scaffolds or scaffold only groups (Fig. 2D).
Pyrintegrin promotes adipogenesis from host endogenous cells without cell transplantation. 
Next, we performed another in vivo experiment to determine whether Ptn promotes endogenous adipogenesis 
without cell transplantation. A total of 10-μ g/mL Ptn was homogenously seeded in 3 mg/mL neutralized type I 
collagen solution (20 μ L). Ptn-adsorbed or Ptn-free collagen solution was infused into PCL scaffold’s microchan-
nels (Fig. 3A), followed by gelation for 1 h at 37 °C. Ptn-adsorbed or Ptn-free PCL scaffolds were implanted in 
the inguinal fat pad in vivo in C57BL/6 mice (N = 6/group) (Fig. 3A). Following 4-wk in vivo implantation, little 
adipose tissue was formed in the representative Ptn-free scaffolds (Fig. 3B). Remarkably, Ptn-adsorbed collagen 
Figure 2. Pyrintegrin induces adipogenesis of transplanted human adipose stem/progenitor cells in vivo. 
(A) Polycaprolactone (PCL) particles were melted and 3D-printed as cylinders, with top and side views and 
microscopic images without and with cells seeded in microchannels. (B) Infusion of human adipose derived 
stem cells (hASCs) in collagen gel into PCL microchannels, followed by implantation in the dorsum of athymic 
mice and retrieved in 4 wks, with a representative sample shown. (C) Representative histology images of in vivo 
retrieved samples stained for lipids by Oil-Red-O dye and nucleus by hematoxylin stain. (D) q RT-PCR analysis 
of human PPARγ , of in vivo retrieved samples. Scale bar: 100 μ m. Data are expressed as mean ± S.D. *P < 0.05.
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gel induced formation of adipose tissue that was positive to Oil Red O (Fig. 3B). Mouse PPARγ expression with 
RNA extracted from in vivo harvested tissue within the scaffold’s microchannels was significantly higher in 
Ptn-adsorbed collagen gel scaffolds than Ptn-free collagen gel scaffolds (Fig. 3C). Given that no cells were trans-
planted, Ptn promotes endogenous adipogenesis in the native adipose environment.
Pyrintegrin attenuates SMAD-dependent BMP signaling. To explore Ptn signaling mechanisms, we 
first performed a human PPARγ luciferase receptor assay. PPARγ activity was unresponsive to Ptn stimulation at 
0.02, 0.2 or 2 μ M, but was promoted by Rosiglitazone, a known potent PPARγ agonists (Fig. 4A,B). Accordingly, 
we screened several known adipogenesis signaling pathways and found that Ptn down-regulated the phospho-
rylation of Smad1/5, a downstream BMP target (Fig. 4C). However, Ptn did not inhibit the phosphorylation of 
p42/44 MAPK (Fig. 4C), a downstream target of MEK1/2 pathway. To further explore whether Ptn acts through 
SMAD-dependent BMP signaling, hASCs were treated with no BMP4, or BMP4 + Ptn (0 to 10 μ M) media. Both 
western blot and densitometry analysis confirm our finding that Ptn inhibited BMP4-mediated phosphorylation of 
BMP responsive SMAD1/5 in a dose-dependent manner (half maximal inhibitory concentration (IC50) = 1.14 μ M), 
(Fig. 4D), but failed to attenuate SMAD2 activation by TGFβ 1 at concentrations equal to or greater than those 
that were inhibitory to BMP signaling (Fig. 4E). Ptn activated phosphorylation of p38 MAPK at higher doses 
(5 and 10 μ M), but not at lower concentrations (Fig. 4F) in the presence of BMP4. p38 MAPK is responsive to 
both cellular non-stress and stress stimuli signals45 and our results suggest that at higher doses of Ptn, the cells 
might be experiencing cytotoxic stress.
Pyrintegrin attenuates osteogenesis and promotes adipogenesis. At 80–90% confluence, hASCs 
were treated with osteogenesis induction medium (OIM), and OIM containing 2-μ M Ptn (Fig. 5A). In com-
parison with expected robust Alizarin Red staining with ASCs in OIM for 21 days, Ptn drastically attenuated 
Alizarin Red staining (Fig. 5A). By 21 days, Ptn significantly attenuated Runx2 and Osx (Fig. 5B,C). Ptn further 
upregulated PPARγ (Fig. 5D) and C/EBPα (Fig. 5E) even in chemically defined medium for osteogenesis. Ptn 
further stimulated lipid droplets in OIM at 7, 14 and 21 days (Fig. 5F). Importantly, Ptn alone failed to induce 
lipid accumulation (Fig. 5F). Given that Ptn induced adipogenesis in OIM but not in DMEM, we compared 
the known ingredients between osteogenesis induction medium and adipogenesis induction medium based on 
common protocols including the ones used in the present study, and found that the only common component is 
dexamethasone (Dex). With a postulation that Dex may have synergistic effect with Ptn in promoting adipogen-
esis, we found that indeed, 2-μ M Ptn and Dex at 0.1-, 1- and 10-μ M concentrations conjunctively promoted lipid 
accumulation for the tested 21 days (Fig. 5G), suggesting that Dex is likely the key ingredient in both osteogenesis 
and adipogenesis induction media that enables Ptn’s ability to promote adipogenesis.
Discussion
The present data provides the first experimental evidence that a small molecule, Ptn is potent in concurrently capable 
of promoting adipogenic differentiation and attenuating osteogenic capability of human ASCs by mediating SMAD 
dependent BMP signaling attenuation in vitro (Fig. 6). It further demonstrates that this small molecule, Ptn pro-
motes adipose tissue formation from either transplanted human adipose stem/progenitor cells or host endogenous 
Figure 3. Pyrintegrin enhances endogenous adipose tissue formation in vivo. (A) Pyrintegrin (Ptn)  
(10 μ g/mL) was adsorbed in collagen gel that was infused in 3D-printed polycaprolactone (PCL) scaffold, 
followed by 1-h incubation at 37 °C and implantation in the inguinal fat pad of C57BL/6 mice. Representative 
sample image following scaffold retrieval after 4 wks. (B) Representative Oil-Red-O images of in vivo retrieved 
scaffold and Ptn-infused scaffold samples. (C) qRT-PCR analysis showing increased mouse PPARγ gene 
expression in Ptn-infused scaffold group. Scale bar: 100 μ m. Data are expressed as means ± SD. *P < 0.05.
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cells. Ptn’s ability to induce in vivo adipogenesis is supported not only by its promotion of crucial adipogenic genes 
including PPARγ and C/EBPα , but also by adipocytokines such as adiponectin and leptin. PPARγ , known as a key 
adipogenesis transcription factor, is activated by prostaglandins and anti-inflammatory agents including indometh-
acin and thiazolidinedione46–48. Ptn appears to signal differently than PPARγ agonists. By itself, Ptn fails to promote 
PPARγ gene expression and thereby does not directly promote adipogenesis. Nonetheless, Ptn robustly promotes 
adipogenesis in the presence of known adipogenic supplements including insulin, dexamethasone, and cAMP acti-
vators. Ptn’s ability to stimulate adipogenesis only in the presence of known adipogenic supplements is supported by 
the outcome of our two in vivo experiments in which adipogenesis is induced not only by Ptn primed adipose stem/
progenitor cells, but also adipogenesis by host endogenous cells. Either way, adipogenesis within the microchannels 
of 3D printed scaffold suggests that transplanted cells or recruited host endogenous cells are the cell sources for adi-
pose tissue formation. In this regard, Pyrintegrin acts similarly to IGF128 that has been shown to orchestrate adipose 
tissue formation from endogenous cells in an existing adipogenic environment.
In multiple bone disorders, stem/progenitor cells differentiate towards adipogenic lineage at the expense of oste-
ogenesis. PPARγ activation with TZDs promotes the differentiation of precursor cells into adipocytes and inhibits 
osteoblast differentiation49. By comparing Ptn with known PPARγ promoters such as Rosiglitazone by perform-
ing human PPARγ luciferase assay, we concluded that Ptn does not appear to be a classic PPARγ agonist. These 
data suggest that Pyrintegrin promotes adipocyte differentiation through a mechanism that is distinctively differ-
ent from that of PPARγ agonists. The functional importance of BMP signaling in promoting adipogenesis is sup-
ported by Ptn’s ability to inhibit osteogenic differentiation and promote lipid accumulation in vitro. BMP responsive 
SMAD1/5/8 promotes osteogenesis by interacting with Runx2 to activate target gene transcription, leading to osterix 
induction50. Since the present data show that Ptn attenuates BMP-mediated SMAD1/5 activity and promotes adipo-
genesis even in osteogenic differentiation medium, we suggest that Ptn mediated BMP signaling might be adjunctive 
to Ptn-induced adipogenesis. The ability of Pyrintegrin to block SMAD1/5/8 phosphorylation in the absence and 
presence of BMP ligand suggests that Ptn attenuates BMP receptor kinase activity. Additional work will test Ptn 
effects in cells lacking BMP type II receptors and understand Pyrintegrin functions in the absence or presence of 
BMP receptors. Inhibition of BMP signaling is typically achieved by sequestering its ligands by administering soluble 
receptor extracellular domains or ligand-specific neutralizing antibodies51–53, or endogenous antagonists such as 
noggin or follistatin54–56. Hence, additional studies utilizing gain-of-function or loss-of function of BMP signaling in 
the presence of Ptn will likely elucidate BMP signaling in Ptn mediated adipogenesis.
Figure 4. Pyrintegrin attenuates BMP-mediated SMAD activation. (A) Ptn chemical structure. (B) Dose response 
of human PPPARγ luciferase assay. RLU, relative light units. (C) MAPK p44/p42 and SMAD1/5 phosphorylation 
by immunoblot after pretreatment with DMEM, AIM, AIM + Ptn and Ptn alone for 1 h. Equivalent protein loading 
confirmed by total SMAD1 and β -actin. (D) Western blot and densitometry analysis of SMAD1/5 phosphorylation 
following Ptn pretreatment for 30 min followed by treatment with BMP4 for 30 min. Equivalent protein loading 
confirmed by detection of total SMAD1 and β -actin. Hill plot of the inhibition of BMP4-stimulated SMAD1/5/8 
phosphorylation by incubating hASCs with Pyrintegrin. (E) SMAD2 phosphorylation treated with BMP4 showing 
virtually negative Ptn effect on BMP4-mediated SMAD2 activity. (F) Ptn attenuated BMP4-mediated MAPK p38 
phosphorylation modestly at concentrations ≥ 5 μ M. Data are expressed as means ± SD. *P < 0.05.
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Pyrintegrin induces lipid accumulation and adipogenic differentiation of adipose stem/progenitor cells in the 
presence of dexamethasone alone and in the absence of insulin and cAMP activators. Dexamethasone is a gluco-
corticoid and known as a potent stimulator for 3T3-L1 and TA-1 preadipocytes57–60. The glucocorticoid receptor 
is a member of the nuclear hormone receptor family and upon ligand binding can directly activate C/EBPδ tran-
scription. The present findings demonstrate that the simultaneous activation of dexamethasone’s canonical sign-
aling pathways, through the glucocorticoid receptor and Ptn through PPARγ and C/EBPα promotes adipogenic 
differentiation. In the absence of Dex alone treatment group, we wish to highlight the role of Dex based on the 
current literature. Dexamethasone (Dex) is known to alter bone marrow61,62 and muscle derived mesenchymal 
stem cells (MSCs) proliferation rate61, and enhances their osteogenic differentiation capability61,63. Dex alone does 
not induce adipogenic differentiation in MSCs over a 16-day culture period64 or in human adipose derived stem 
cells65. Dex and Rosiglitazone together are necessary and sufficient to induce adipogenic differentiation in MSCs35 
Figure 5. Pyrintegrin attenuates osteogenic differentiation in vitro. (A) Alizarin Red staining following 
treatment of adipose stem/progenitor cells (ASCs) in osteogenesis induction medium (OIM) and 
OIM+Pyrintegrin (Ptn) for 3 wks. (B,C) Time-course qPCR analysis of Runx2, Osx, PPARγ and C/EBPα 
mRNA expression measured over 21 days. (F) Lipid staining of hASCs treated with OIM, OIM+Ptn and Ptn 
alone at Days 7, 14 and 21. (G) Lipid staining of hASCs exposed to 2-μ M Ptn and multiple dexamethasone 
doses (0, 0.1, 1 and 10 μ M) for 21 days.
Figure 6. Proposed model for the role of Ptn signaling in hASCs. See discussion for details.
www.nature.com/scientificreports/
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and therefore we tested the effect of Pyrintegrin in the presence of Dex. Remarkably, lipid droplet formation and 
mineralization occur concurrently in response to Ptn treatment during osteogenesis.
Taken together, the present data show that Ptn promotes adipogenesis in an adipogenic environment either 
by Ptn-primed ASCs or host endogenous cells in Ptn-adsorbed scaffolds implanted in the inguinal fat pad. For 
translational studies, Ptn’s efficacy to promote endogenous adipogenesis without cell transplantation clearly 
offers advantages, similar to our previous work on tissue regeneration by cell homing, without the need for cell 
transplantation43,44,66,67. Pyrintegrin may offer potential advantages of tunable doses as a potential treatment 
for lipoatrophy, and an alternative to autologous fat transfer that has an intrinsic disadvantage of unpredictable 
post-operative volume reduction. Ptn attenuation of osteogenesis may have potential usage in promoting soft 
tissue healing and avoiding ectopic mineralization. Nevertheless, when using a small molecule the possibility of 
confounding effects from secondary targets should be considered, which we did not see in our in vivo studies due 
to the lowest effective concentration used. This study further warrants a more detailed and different dose analysis 
to maximize selectivity for effective adipogenic signaling.
Methods
Human adipose stem/progenitor cells. All experimental protocols were approved by Columbia 
University’s IRB approval and were carried out in accordance with their outlined guidelines and regulations. 
Human adipose stem/progenitor cells (hASCs) were isolated from lipectomy samples (anonymous female donors; 
age: 37 to 52 years old) per our prior methods2,11,16,17. We also obtained lipoaspirate-extracted ASCs from dif-
ferent donors from Dr. Farshid Guilak’s laboratory at Duke University Medical Center as a generous gift. An 
informed consent was obtained from all the human subjects whose tissue samples were utilized for this study 
design. Growth medium (DMEM) was defined as Dulbecco’s modified Eagle’s medium:Nutrient mixture F12 
(DMEM/F12+GlutamaxTM-I; Life Technologies, Grand Island, NY), 1% antibiotic (Antibiotic–Antimycotic 100X 
contains 10000 units of Penicillin, 10000 μ g of Streptomycin and 25 μ g of amphotericin B; Gibco, Invitrogen 
Corporation, Carlsbad, CA) and 10% Fetal Bovine Serum (FBS; Life Technologies, Grand Island, NY). Frozen 
cells were allowed to thaw in a 37 °C water-bath for 2 min and suspended in fresh DMEM. Cell suspension was 
centrifuged at 300 g for 5 min with cell pellet resuspended in fresh DMEM and plated in 5% CO2 at 37 °C. Medium 
was changed twice per week until the cells become confluent. Upon 80‐90% confluence, cells were washed, 
trypsinized, centrifuged, and resuspended in -DMEM as passage 1 (P1) and plated at a ratio of 1:4 or frozen in 
a freezing solution (80% (vol/vol) FBS, 10% (vol/vol) DMEM/Ham’s F-12 and 10% (vol/vol) Dimethyl sulfoxide 
(DMSO; Sigma-Aldrich, St. Louis, MO) and stored in liquid nitrogen, per our previous methods2,11,17. Cells were 
counted using 0.4% Trypan blue and Countess Automated cell counter (Invitrogen Corporation, Carlsbad, CA).
Multi-lineage differentiation. Cells were treated with adipogenic induction medium (AIM) containing 
1-μ M dexamethasone (Dex), 10-μ g/ml insulin, 0.5-μ M isobutylmethylxanthine (IBMX) and 60-μ M indomethacin 
(Sigma-Aldrich, St. Louis, MO) per our prior methods2,10,11,16,17. Human ASCs treated with growth medium and 
DMSO (vehicle) without adipogenic supplements represented DMEM cultures. Human ASCs treated with adi-
pogenic induction medium represented AIM cultures. Human ASCs treated with adipogenic medium containing 
Pyrintegrin dissolved in DMSO represented AIM + Ptn cultures. For osteogenic differentiation, cells were treated 
with osteogenic induction medium (OIM) containing 100-nM Dex, 0.05-mM L-ascorbic acid-2-phosphate, and 
10-mM β -glycerophosphate disodium salt hydrate (Sigma-Aldrich). All experiments were performed in triplicates.
Pyrintegrin treatment of adipose stem/progenitor cells. To optimize the effective Ptn doses for adi-
pogenic differentiation, Passage 5 (P5) ASCs were culture‐expanded in monolayer at a density of 5 × 103 cells/cm2. 
At 80–90% confluence, ASCs were treated with DMEM, AIM and AIM supplemented with 2, 5 and 10 μ M- Ptn. 
To understand the long-term effects of Ptn on adipogenic differentiation potential of hASCs, P5 hASCs were 
treated with DMEM, AIM, AIM supplemented with 2-μ M Ptn (AIM + Ptn 2 μ M) and DMEM supplemented with 
2-μ M Ptn (Ptn 2 μ M only) for 28 days.
Real Time qRT-PCR. Total RNA was isolated using PureLink RNA Mini kit (Life Technologies, Grand Island, NY) 
per manufacturer’s instructions. RNA samples were eluted in 30-μ l DEPC‐water. Total RNA was quantified using 
NanoDrop 1000 Spectrophotometer (Invitrogen, Carlsbad, CA) and stored at − 80 °C prior to reverse transcrip-
tion. All RNA samples were reverse-transcribed using a High‐Capacity cDNA Reverse Transcription kit (Applied 
Biosystems, Foster City, CA). The cDNA was synthesized using 0.1–0.2 μ g RNA to obtain 20-μ L cDNA. All cDNA 
samples were stored at ‐20 °C until further use. For qPCR reactions, cDNA samples were mixed with TaqMan® 
Universal PCR Master Mix (Applied Biosystems, Foster City, CA), primers, and nuclease‐free water per manufac-
turer’s protocol. PCR primers included peroxisome proliferator-activated receptor γ (PPARγ , Hs01115513_m1), 
and CCAT-enhanced binding protein α (C/EBPα , Hs00269972_s1) gene-specific FAM dye tagged primers. Osteogenic 
markers included Runt-related transcription factor 2 (RunX2, Hs00231692_m1), and Osterix (Sp7, Hs01866874_s1) 
gene-specific FAM dye tagged primers (Applied Biosystems, Carlsbad, CA). All mRNA was measured using ViiA™ 7 
Real-Time PCR System (Applied Biosystems) in 25-μ l reaction volume, with GAPDH as a house-keeping gene.
Lipid staining. Human ASC cultures were washed with PBS (Sigma-Aldrich), fixed in warmed 4% paraformalde-
hyde solution (Fisher-Scientific, Pittsburgh, PA) for 10–30 min at room temperature. Cells were gently washed twice 
with PBS and then stained with LipidTOXTM neutral lipid stain (Invitrogen) for 10–15 min per our prior methods.
Adipogenesis assays. Human ASCs were plated at 5 × 103/cm2 and differentiated in chemically defined 
medium for 28 days. Culture medium and lysed cell supernatant were individually collected on 14 and 28 days. 
Cells were lysed using 1% Triton-X solution (Sigma-Aldrich, St. Louis, MO). Cell culture lysate was collected 
by scrapping with a cell scraper (Fisher-Scientific) and briefly sonicated for 10 s using an ultrasonic water bath 
www.nature.com/scientificreports/
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(Fisher-Scientific) on ice. Total secreted human adiponectin and leptin were measured using ELISA (R&D, 
Minneapolis, MN) per our prior methods2,10,11,16,17. Absorbance was read using a microplate reader (Biorad, 
Hercules, CA). DNA content was measured using Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies) 
per our prior methods. A high-range standard curve of 1 μ g/mL was used for measuring the DNA con-
centration of the samples per our prior methods. The samples were prepared in a 96 well black bottom plate 
(Fisher-Scientific) with absorbance read using microplate reader and standard fluorescein wavelengths (excita-
tion ~480 nm, emission ~520 nm; Molecular Devices, Sunnyvale, CA). Total triglycerides and glycerol contents 
were measured by processing the sample lysate with Free Glycerol Determination kit (Sigma-Aldrich) per our 
prior methods2,10,11,16,17.
Scaffold design and synthesis. Scaffold design and synthesis followed our previous methods to cre-
ate 3D printed scaffolds with interconnecting microchannels43,44,66,67. Using 100 wt% poly-ε -caprolactone, 
PCL (Sigma-Aldrich Corp.,) with molecular weight ~65 KDa was 3D-printed using a bioplotter (EnvisionTec, 
Gladbeck, Germany). PCL pellets were first melt at 120 °C and then printed layer-by-layer as a cylinder (5 × 3 mm: 
diameter × height) using CAD software. Interlaid strands had diameters of 250–300 μ m and interconnecting 
microchannels had a diameter of 400–500 μ m. Scaffolds were sterilized in Ethylene Oxide (ETO) gas (Anprolene 
AN74i, Fisher, Pittsburgh, PA).
Cell seeding in scaffolds. Cells were washed, trypsinized, counted and seeded at a density of 10 × 106 cells/
mL by mixing the cells with 3 mg/mL Collagen Type I solution (BD Bioscience, Sparks, MD). Collagen solution 
was allowed to crosslink for 1 h at 37 °C before in vivo implantation. Sample size per group was 6.
In vivo implantation of cell-seeded scaffolds. All experimental protocols were approved by Columbia 
University’s Institutional Animal Care and Use Committee (IACUC) and were performed in accordance with 
their guidelines and regulations. Athymic nude male mice (7–8 wks old; Harlan, Indianapolis, IN) were anes-
thetized with intraperitoneal ketamine (100 mg/kg) and xylazine (5 mg/kg), and maintained at 1–3% isoflurane 
(Fisher-Scientific). The skin was disinfected with 70% Ethanol and wiped with Betadine and Povidone-Iodine 
(Fisher-Scientific). Following a linear midsaggital incision, subcutaneous pockets were created using fine scissors 
and housed all in vivo implanted scaffolds, followed by skin closure with a 4–0 P-3 vicryl coated undyed braided 
suture (Ethicon, Somerville, NJ). All mice received post-surgical Rimadyl IP injections for pain control (5 mg/
kg, Pfizer, New York, NY). All scaffolds were retrieved after 4 wks following euthanasia with CO2 asphyxiation.
In vivo implantation of Pyrintegrin adsorbed scaffolds. A total of 3 mg/mL neutralized collagen type 
I solution was prepared per our prior method43,44,66,67 with 10 μ g/mL Ptn adsorbed. Ptn-adsorbed or Ptn-free 
collagen gel was infused into the scaffolds’ microchannels by pipetting, followed by collagen crosslinking for 1 h 
at 37 °C before in vivo implantation. Following Columbia University IACUC approval, C57BL/6 male mice (age: 
10–11 wks, weight 15–25 g; Harlan, Indianapolis, IN) were fed with adjusted irradiated calories diet (Harlan). 
Given the mouse susceptibility to diet-induced obesity, the mice gained ~10–15 g in 6 wks (data not shown), 
after which we surgically implanted Ptn-adsorbed and collagen gel alone scaffolds in separate mice (N = 6 per 
group). On the day the surgery, the mice were anesthetized with 3–5% isoflurane. The skin was disinfected with 
70% Ethanol, Betadine and Povidone-Iodine. An 1–1.5 cm long incision was made in the upper segment of the 
hindlimbs on both sides to expose the inguinal fat pad. A small pocket was created using fine dissecting scissors 
in this fat pad followed by implantation of Ptn-adsorbed or collagen gel only scaffolds, and closure of fat pad 
and skin using a 4–0 P-3 vicryl coated undyed braided suture. All mice received post-surgical Rimadyl IP injec-
tions for pain control (5 mg/kg, Pfizer). All scaffolds were retrieved after 4 wks following euthanasia with CO2 
asphyxiation.
Histology and immunohistochemistry. The retrieved scaffolds were embedded in optimal cutting tem-
perature medium (Fisher-Scientific) in cryomolds and frozen in isopentane (Fisher-Scientific) pre-cooled in liq-
uid nitrogen and processed for cryosectioning (Histoserv, Germantown, MD) into 8-μ m sections. Frozen sections 
were fixated in 4% paraformaldehyde (Fisher-Scientific) at room temperature for 15 min, permeabilized with 
0.25% Triton X-100 (Sigma-Aldrich, St. Louis, MO) and blocked with Licor Odyssey Blocking buffer (Licor) and 
stained with Oil Red O and hematoxylin.
Human PPARγ reporter assay. PPAR Reporter assay kit (Indigo Biosciences, State College, PA) utiliz-
ing non-human mammalian cells engineered to express constitutive, high-level expression of human PPARγ , 
a ligand-dependent transcription factor. These reporter cells include the luciferase reporter gene functionally 
linked to a PPARγ -responsive promoter. Thus, quantifying changes in luciferase expression in the treated reporter 
cells provides a sensitive surrogate measure of the changes in PPARγ activity. Rosiglitazone was used as a positive 
control due to its ability to bind to the nuclear PPARγ receptor. As per manufacturer’s instructions, the reporter 
cells were plated and immediately treated with Rosiglitazone or different Ptn doses. No adipogenic inductive fac-
tors were used in this assay. Following overnight incubation at 37 °C, the treated medium was discarded followed 
by addition of 100-μ l luciferase detection reagent (LDR), and incubation at room temperature for 15 min. Light 
intensity emitted was quantified using a plate-reading luminometer.
Western blot. Cells were treated with growth (DMEM), adipogenesis induction medium (AIM), AIM con-
taining 2-μ M Ptn (AIM + Ptn) or 2-μ M Ptn supplemented DMEM for 1 h, and then harvested in lysis buffer 
(50-mM Tris-HCl; pH 8), 1% NP40, 150-mM NaCl, phosphatase Inhibitor, protease Inhibitor for 20 min on 
ice. Cell extracts were centrifuged at 12,000 × g for 20 min at 4 °C. Protein concentration was measured using a 
Bradford Protein assay (Bio-Rad, Hercules, CA). A total of 20-μ g protein was denatured at 70 °C for 10 min and 
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separated on a 4–12% NuPAGE Novex Bis-Tris gel electrohoresis (Invitrogen), followed by transferring of pro-
tein onto a PVDF membrane (Biorad). The membrane was blocked using Odyssey blocking buffer, rocked on a 
shaker for 30 min, and immunoblotted overnight with phospho-p42/p44 MAPK, phospho-SMAD1/5, SMAD1 
primary antibodies at 4 °C (Cell Signaling Technologies, Danvers, MA) and β -Actin (Santa Cruz Biotechnology, 
Paso Robles, CA). Specifically bound primary antibodies were detected by incubating for 1 h with ALP conjugated 
secondary antibodies and enhanced using 1-Step NBT/BC1P (Fisher Scientific).
Immunobloting of BMP and TGFβ-responsive SMAD phosphorylation. ASCs were plated at 5 × 103 
cm2 per 10-cm petridish for SMAD signaling and MAPK p38 signaling. For SMAD1/5 and MAPK p38 signaling 
studies, the cells were serum-starved overnight and treated with DMEM/F12 medium and vehicle or DMEM/
F12 medium and vehicle containing 30 ng/mL BMP4 and varying Ptn doses (0, 0.2, 0.5, 1, 2, 5, and 10 μ M) for 
1 h. For SMAD2 signaling studies, the cells were serum-starved overnight and treated with DMEM/F12 medium 
and vehicle or DMEM/F12 medium and vehicle containing 0.5 ng/mL TGFβ 1 and varying Ptn doses for 1 h. Cell 
extracts were mechanically homogenized in lysis buffer, separated by NuPAGE Bis-Tris gels, immunoblotted with 
anti-phospho-SMAD1/5, anti-SMAD1, anti-phospho-SMAD2, anti-phospho-p38 MAPK, anti-p38 MAPK (Cell 
Signaling) or anti-β -Actin primary antibodies, and Alexa Flour 680 goat anti-rabbit IgG or Alexa Flour 680 goat 
anti-mouse IgG (Invitrogen) and visualized using Odyssey Infrared Imager (Licor).
Alizarin Red staining. ASCs were seeded onto a 24 well plates and treated with osteogenesis induction 
medium (OIM) with or without 2-μ M Ptn for 3 wks. Cells were fixed in warmed 4% paraformaldehyde and 
stained with Alizarin Red S stain (Sigma-Aldrich) for 5 min as per manufacturer’s protocol.
Dexamethasone treatment. ASCs were seeded at 5 × 103 cells/cm2 in 24 well plates. After cells were 
exposed to 2-μ M Ptn in DMEM with different dexamethasone doses (0.1 to 10 μ M) for 3 wks, culture medium 
was removed with cells stained for lipid visualization.
Statistical analysis. Upon confirmation of normal distribution, all quantitative data were analyzed using 
a one‐way analysis of variance (ANOVA) with post‐hoc Bonferroni tests to determine significant differences 
between or within groups, using a statistical package (SPSS, Chicago, IL). Results were considered significant for 
p < 0.05.
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